Abstracts Of Interest At The 78th Ada Scientific Sessions | Latest News RSS feed

Abstracts Of Interest At The 78th Ada Scientific Sessions - Latest News


Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

2018 - Zealand Pharma ("Zealand") announces today that results from two studies on dasiglucagon will be presented at the 78th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, ... read more

AstraZeneca to present 45 abstracts from CVRM therapy area at ADA 2018

will present 45 abstracts including seven late-breaking data disclosures from the company's cardiovascular, renal & metabolism (CVRM) therapy area at the American Diabetes Associations (ADA) 78th Scie... read more

Call for Nominations: ADA 2018 Professional Interest Group Awards

15 (8 p.m. ET), the American Diabetes Association is seeking nominations for the 2018 Professional Interest Group Awards to ... presented at the 78th Scientific Sessions in Orlando, June 22-26, 2018. ... read more

Looking for another news?


Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update

78th Scientific Sessions and showed that leptin replacement therapy sustainably decreased weight over time in patients with low baseline leptin levels. Novelion and Aegerion’s ability to ... read more


Zafgen, Inc. (ZFGN) CEO Jeffrey Hatfield on Q2 2018 Results - Earnings Call Transcript

The highlight of the second quarter was our presentation of multiple late-breaker abstracts at the American Diabetes Association or ADA Scientific Sessions in late June ... use associated with medical ... read more

IBM Watson Health Showcases Health Technology Advancements at American Diabetes Association's 78th Scientific Sessions

as presented at the American Diabetes Association's (ADA) 78th Scientific Sessions. Through IBM Watson Health's ongoing partnership with Medtronic, the companies announced the commercial availability ... read more

AstraZeneca to share latest data from a leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA

will present 45 abstracts including seven late-breaking data disclosures from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the American Diabetes Association’s (ADA) 78th Sci... read more

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

1 The new data will be presented tomorrow, 24 June, 2018 at the American Diabetes Association's 78 th Scientific Sessions (ADA) in Orlando ... PIONEER 1 Trial. Abstract 2-LB. Presented at the 78th Sci... read more

Timely News and Notes for Primary Care Providers from the American Diabetes Association

Results of the PIONEER 1 study were also released at the ADA’s 78th Scientific Sessions (bit.ly/2ngKotY), showing that treatment with any of three doses of oral semaglutide achieved significantly grea... read more

MannKind's (MNKD) CEO Michael Castagna on Q1 2018 Results - Earnings Call Transcript

Coming into this quarterly call, I've conducted 10 listening sessions ... We have scientific information being presented at the ADA. We hope to have additional scientific information presented at each ... read more

Alizé Pharma to present phase I trial results from unacylated ghrelin analog, AZP-531 at ADA scientific sessions

The ADA Scientific Sessions bring together over 14,000 participants ... The programme includes five days of comprehensive, unparalleled education through symposia, oral abstract sessions, interest gro... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us